Share: Facebook Twitter GooglePLus LinkedIn
Activity Provided By:

CME Outfitters

Honing in on the Appeal Process to Improve Access to Anti-VEGF Therapy for Patients with AMD

Access Activity

Overview / Abstract:

Step therapy requirements have limited patient access to FDA-approved, anti–vascular endothelial growth factor (VEGF) agents for the treatment of AMD. Prior authorization requests for these therapies are commonly denied. Hence, it is important that clinicians be aware of the approaches to overcome these barriers and implement systematic and clinically supported appeals that ensure uninterrupted anti-VEGF therapy for patients with AMD.

In the third module of this CME Outfitters Snack series, expert faculty focus on developing and implementing strategies for appeals in order to reduce treatment delays.


Nov 21, 2020


Nurse Practitioner , Nursing CNE, Pharmacy CPE, Physician CME, Physician Assistant CME


Online, Webinar / Webcast / Video

Credits / Hours

0.5 AMA PRA Category 1 Credit(s)™/contact hours/CEUs



Presenters / Authors / Faculty

Darius M. Moshfeghi, MD
Professor and Chief, Retina Division
Horngren Family Vitreoretinal Center
Byers Eye Institute, Department of Ophthalmology
Stanford University School of Medicine
Stanford, CA

Derek van Amerongen, MD, MS
Vice President and Medical Officer
Humana of Ohio
Springdale, OH

Sponsors / Supporters / Grant Providers

This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

Keywords / Search Terms

CME Outfitters, LLC macular degeneration, optical, ophthalmology, optical disease, AMD, age-related macular degeneration Free CE CME

Access Activity

RXinsider,, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the website or within our mobile apps. RXinsider,, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the Terms of Service. Site Map.